Company / SG&A Expense
BioNexus Gene Lab Corp SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.5M
FY2025
5-year range
$1.3M / $2.4M
FY2021-FY2025
Trend
-16.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has fluctuated over the past 7 years, ranging from $356,641 in FY2019 to $2M in FY2023.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of +2.9%.
Improved from $2M to $2M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -3.9%
- 5-Year CAGR
- +2.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +2.9%, indicating consistent growth.
- In FY2025, sg&a expense decreased 16.2% year-over-year.
- Peak sg&a expense was recorded in FY2023.
- Lowest sg&a expense in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.5M | -16.2% |
| FY2024 | $1.8M | -25.0% |
| FY2023 | $2.4M | +41.2% |
| FY2022 | $1.7M | +35.4% |
| FY2021 | $1.3M | -4.2% |
| FY2020 | $1.3M | +273.7% |
| FY2019 | $356.6K | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026